Send me real-time posts from this site at my email
Zacks

Agilent (A) Q3 Earnings Surpass Estimates, Revenues Rise Y/Y

Agilent Technologies A reported third-quarter fiscal 2022 earnings of $1.34 per share, beating the Zacks Consensus Estimate by 11.7%. The bottom line increased 21.8% year over year and 18.6% sequentially.

Revenues of $1.72 billion surpassed the Zacks Consensus Estimate by 4.9%. The top line was up 8% on a reported basis and 13% on a core basis from the respective year-ago quarter’s levels. Revenues increased 6.9% from the prior quarter’s figure.

Top-line growth was driven by continued strong growth in the pharma market. Also, solid momentum in the chemical & energy market remained positive.

Agilent Technologies, Inc. Price, Consensus and EPS Surprise

Agilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. Quote

Segmental Top-Line Details

Agilent has three reporting segments, namely Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG).

LSAG: The segment accounted for $1.02 billion or 59% of its total revenues, up 14% on a reported basis and 18% on a core basis from the respective prior-year quarter’s levels. This was driven by a positive environment across the Pharma, Chemical & Energy, Food, and Environmental & Forensics markets. Growth in LC & LC-MS instruments and Spectroscopy, Consumables and Chemistries, and Cell Analysis platforms also aided results.

ACG: Revenues from the segment were $359 million, accounting for 21% of total revenues. Also, the top line improved 5% year over year on a reported basis and 10% on a core basis, driven by growth in instrument sales. Strong performance of lab activity in China also drove the segment’s results.

DGG: Revenues decreased 2% year over year on a reported basis but rose 3% on a core basis to $340 million, accounting for the remaining 20% of total revenues. The metric was negatively impacted by the shutdown of NASD facility. Nevertheless, strong performance across clinical cancer testing and NGS businesses benefited the results.

Operating Results

For the fiscal third quarter, gross margin in the LSAG segment expanded 10 basis points (bps) on a year-over-year basis to 60.5%. DGG’s gross margin expanded 50 bps on a year-over-year basis to 54%. ACG gross margin expanded 40 bps to 47%.

Research & development costs were $116 million, up 2.7% year over year. Selling, general & administrative expenses were $412 million, up 2.2% year over year.

Operating margin for the fiscal third quarter was 27.5%, expanding 150 bps on a year-over-year basis.

Segment wise, the operating margin for LSAG was up 260 bps year over year to 30.5%. The DGG segment’s operating margin contracted 110 bps on a year-over-year basis to 21.5%. ACG’s operating margin was 24.6%, which expanded 20 bps from the year-ago quarter’s level.

Balance Sheet

As of Jul 31, 2022, Agilent’s cash and cash equivalents were $1.07 billion, down from $1.19 billion on Apr 30, 2022.

Accounts receivables were $1.35 billion at the end of third-quarter fiscal 2022, up from $1.24 billion at the end of second-quarter fiscal 2022.

Long-term debt was $2.732 billion for the reported quarter, up from $2.730 billion in the prior quarter.

Outlook

For the fiscal fourth quarter, management expects revenues of $1.750-$1.775 billion, suggesting growth between 10.3% and 11.8% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for revenues stands at $1.77 billion.

Non-GAAP earnings per share are expected to be $1.38-1.40. The Zacks Consensus Estimate for earnings is pegged at $1.35 per share.

For fiscal 2022, management anticipates revenues in the band of $6.750-$6.775 billion, implying growth of 6.8-7.2% on a reported basis and 9.9-10.3% on a core basis from the respective fiscal 2021 tallies. The Zacks Consensus Estimate for full-fiscal revenues is pegged at $6.69 billion.

Management raised its guidance for non-GAAP earnings per share from $4.86-$4.93 to $5.06-$5.08. The Zacks Consensus Estimate for earnings is pegged at $4.88 per share.

Zacks Rank & Stocks to Consider

Currently, Agilent carries a Zacks Rank #4 (Sell).

Investors interested in the broader Zacks Computer & Technology sector can consider some better-ranked stocks like Arista Networks ANET,Keysight Technologies KEYS and ASE Technology ASX. While Arista Networks sports a Zacks Rank #1 (Strong Buy), Keysight Technologies and ASE Technology carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Arista Networks has lost 9.6% in the year-to-date period. The long-term earnings growth rate for ANET is currently projected at 18.9%.

Keysight Technologies has lost 17.4% in the year-to-date period. KEYS’ long-term earnings growth rate is currently projected at 9.1%.

ASE technology has lost 19.2% in the year-to-date period. The long-term earnings growth rate for ASX is currently projected at 23.1%.


Want to Know the #1 Semiconductor Stock for 2022?

Few people know how promising the semiconductor market is. Over the last couple of years, disruptions to the supply chain have caused shortages in several industries. The absence of one single semiconductor can stop all operations in certain industries.

This year, companies that create and produce this essential material will have incredible pricing power. For a limited time, Zacks is revealing the top semiconductor stock for 2022. You'll find it in our new Special Report, One Semiconductor Stock Stands to Gain the Most.

Today, it's yours free with no obligation.

>>Give me access to my free special report.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Agilent Technologies, Inc. (A): Free Stock Analysis Report
 
ASE Technology Holding Co., Ltd. (ASX): Free Stock Analysis Report
 
Arista Networks, Inc. (ANET): Free Stock Analysis Report
 
Keysight Technologies Inc. (KEYS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue